Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial.


Journal

The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 30 04 2024
revised: 12 07 2024
accepted: 29 08 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 25 9 2024
Statut: ppublish

Résumé

Prospective randomized trials have not yet identified baseline features predictive of organ preservation in locally advanced rectal cancers treated with total neoadjuvant therapy and a selective watch-and-wait strategy. This was a secondary analysis of the OPRA trial, which randomized patients with stage II-III rectal adenocarcinoma to receive either induction or consolidation total neoadjuvant therapy. Patients were recommended for total mesorectal excision, or watch and wait based on clinical response at 8 ± 4 weeks after completing treatment. Standardized baseline clinical and radiological variables were collected prospectively. Survival outcomes, including total mesorectal excision-free survival, disease-free survival, and overall survival, were assessed by intention-to-treat analysis. Cox proportional hazards models were used to evaluate associations between baseline variables and survival outcomes. Of the 324 patients randomized for the OPRA trial, 38 (11.7%) had cT4 tumours, 230 (71.0%) cN-positive disease, 101 (32.5%) mesorectal fascia involvement, and 64 (19.8%) extramural venous invasion. Several baseline features were independently associated with recommendation for total mesorectal excision on multivariable analysis: nodal disease (HR 1.66, 95% c.i. 1.12 to 2.48), extramural venous invasion (HR 1.57, 1.07 to 2.29), mesorectal fascia involvement (HR 1.45, 1.01 to 2.09), and tumour length (HR 1.11, 1.00 to 1.22). Of these, nodal disease (HR 2.02, 1.15 to 3.53) and mesorectal fascia involvement (HR 2.02, 1.26 to 3.26) also predicted worse disease-free survival. Age (HR 1.03, 1.00 to 1.06) was associated with overall survival. Baseline MRI features, including nodal disease, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict the likelihood of organ preservation after completion of total neoadjuvant therapy. Mesorectal fascia involvement and nodal disease are associated with disease-free survival.

Sections du résumé

BACKGROUND BACKGROUND
Prospective randomized trials have not yet identified baseline features predictive of organ preservation in locally advanced rectal cancers treated with total neoadjuvant therapy and a selective watch-and-wait strategy.
METHODS METHODS
This was a secondary analysis of the OPRA trial, which randomized patients with stage II-III rectal adenocarcinoma to receive either induction or consolidation total neoadjuvant therapy. Patients were recommended for total mesorectal excision, or watch and wait based on clinical response at 8 ± 4 weeks after completing treatment. Standardized baseline clinical and radiological variables were collected prospectively. Survival outcomes, including total mesorectal excision-free survival, disease-free survival, and overall survival, were assessed by intention-to-treat analysis. Cox proportional hazards models were used to evaluate associations between baseline variables and survival outcomes.
RESULTS RESULTS
Of the 324 patients randomized for the OPRA trial, 38 (11.7%) had cT4 tumours, 230 (71.0%) cN-positive disease, 101 (32.5%) mesorectal fascia involvement, and 64 (19.8%) extramural venous invasion. Several baseline features were independently associated with recommendation for total mesorectal excision on multivariable analysis: nodal disease (HR 1.66, 95% c.i. 1.12 to 2.48), extramural venous invasion (HR 1.57, 1.07 to 2.29), mesorectal fascia involvement (HR 1.45, 1.01 to 2.09), and tumour length (HR 1.11, 1.00 to 1.22). Of these, nodal disease (HR 2.02, 1.15 to 3.53) and mesorectal fascia involvement (HR 2.02, 1.26 to 3.26) also predicted worse disease-free survival. Age (HR 1.03, 1.00 to 1.06) was associated with overall survival.
CONCLUSION CONCLUSIONS
Baseline MRI features, including nodal disease, extramural venous invasion, mesorectal fascia involvement, and tumour length, independently predict the likelihood of organ preservation after completion of total neoadjuvant therapy. Mesorectal fascia involvement and nodal disease are associated with disease-free survival.

Identifiants

pubmed: 39319400
pii: 7774520
doi: 10.1093/bjs/znae246
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R01CA182551
Pays : United States

Investigateurs

S Patil (S)
J K Kim (JK)
H M Thompson (HM)
M R Marco (MR)
M Lee (M)
P B Paty (PB)
M R Weiser (MR)
G M Nash (GM)
E Pappou (E)
I H Wei (IH)
M Widmar (M)
N H Segal (NH)
A Cercek (A)
R Yaeger (R)
J J Smith (JJ)
A J Wu (AJ)
L B Saltz (LB)
R F Dunne (RF)
L Temple (L)
J Marcet (J)
P Cataldo (P)
B Polite (B)
D O Herzig (DO)
D Liska (D)
S Oommen (S)
C M Friel (CM)
C Ternent (C)
A L Coveler (AL)
S Hunt (S)
A Gregory (A)
M G Varma (MG)
B L Bello (BL)
J C Carmichael (JC)
J Krauss (J)
A Gleisner (A)
J G Guillem (JG)
K A Goodman (KA)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Hannah Williams (H)

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Jonathan B Yuval (JB)

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Surgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Floris S Verheij (FS)

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Joao Miranda (J)

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Sabrina T Lin (ST)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Dana M Omer (DM)

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Li-Xuan Qin (LX)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Marc J Gollub (MJ)

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Tae-Hyung Kim (TH)

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Julio Garcia-Aguilar (J)

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH